EAM Investors LLC cut its holdings in Calithera Biosciences, Inc. (NASDAQ:CALA) by 19.9% in the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 84,668 shares of the biotechnology company’s stock after selling 20,982 shares during the quarter. EAM Investors LLC owned 0.24% of Calithera Biosciences worth $1,257,000 as of its most recent SEC filing.

Several other institutional investors have also bought and sold shares of CALA. Wellington Management Group LLP purchased a new stake in shares of Calithera Biosciences in the first quarter valued at approximately $47,550,000. FMR LLC increased its position in shares of Calithera Biosciences by 85.8% in the second quarter. FMR LLC now owns 2,717,090 shares of the biotechnology company’s stock valued at $40,349,000 after buying an additional 1,254,900 shares in the last quarter. RA Capital Management LLC purchased a new stake in shares of Calithera Biosciences in the first quarter valued at approximately $8,374,000. Bogle Investment Management L P DE purchased a new stake in shares of Calithera Biosciences in the first quarter valued at approximately $5,732,000. Finally, Vanguard Group Inc. increased its position in shares of Calithera Biosciences by 99.8% in the first quarter. Vanguard Group Inc. now owns 925,015 shares of the biotechnology company’s stock valued at $10,684,000 after buying an additional 462,137 shares in the last quarter. Institutional investors and hedge funds own 71.88% of the company’s stock.

A number of analysts have recently commented on CALA shares. Zacks Investment Research upgraded Calithera Biosciences from a “hold” rating to a “strong-buy” rating and set a $21.00 price objective for the company in a research report on Tuesday, July 11th. Wells Fargo & Company restated an “outperform” rating and issued a $20.00 price objective (up from $15.00) on shares of Calithera Biosciences in a research report on Tuesday, June 6th. BidaskClub cut Calithera Biosciences from a “sell” rating to a “strong sell” rating in a research report on Saturday, August 12th. Finally, HC Wainwright restated a “buy” rating and issued a $19.00 price objective (up from $14.00) on shares of Calithera Biosciences in a research report on Monday, June 12th. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating and four have issued a buy rating to the stock. Calithera Biosciences has an average rating of “Hold” and a consensus target price of $15.50.

Shares of Calithera Biosciences, Inc. (CALA) opened at 15.30 on Thursday. The stock’s market capitalization is $542.78 million. The company’s 50 day moving average price is $15.09 and its 200 day moving average price is $14.12. Calithera Biosciences, Inc. has a 12 month low of $2.20 and a 12 month high of $20.05.

Calithera Biosciences (NASDAQ:CALA) last released its quarterly earnings results on Tuesday, August 8th. The biotechnology company reported ($0.15) earnings per share for the quarter, topping the consensus estimate of ($0.29) by $0.14. The company had revenue of $7.26 million for the quarter, compared to analysts’ expectations of $4.80 million. Equities analysts anticipate that Calithera Biosciences, Inc. will post ($0.83) earnings per share for the current fiscal year.

In other news, VP Keith Orford sold 2,120 shares of the firm’s stock in a transaction on Monday, July 17th. The stock was sold at an average price of $18.31, for a total transaction of $38,817.20. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. 16.30% of the stock is owned by company insiders.

COPYRIGHT VIOLATION WARNING: “Calithera Biosciences, Inc. (CALA) Stake Lowered by EAM Investors LLC” was originally reported by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this story on another domain, it was copied illegally and republished in violation of international trademark and copyright legislation. The legal version of this story can be viewed at https://www.thecerbatgem.com/2017/09/28/calithera-biosciences-inc-cala-stake-lowered-by-eam-investors-llc.html.

Calithera Biosciences Company Profile

Calithera Biosciences, Inc is a clinical-stage pharmaceutical company. The Company focuses on discovering and developing small molecule drugs directed against tumor and immune cell targets that control key metabolic pathways in the tumor microenvironment. It is engaged in developing agents that take advantage of the metabolic requirements of tumor cells and cancer-fighting immune cells, such as cytotoxic T-cells.

Want to see what other hedge funds are holding CALA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Calithera Biosciences, Inc. (NASDAQ:CALA).

Institutional Ownership by Quarter for Calithera Biosciences (NASDAQ:CALA)

Receive News & Stock Ratings for Calithera Biosciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Calithera Biosciences Inc. and related stocks with our FREE daily email newsletter.